Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2015 1
2016 2
2017 3
2018 2
2019 3
2020 4
2021 2
2022 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean manito n (142 results)?
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, Danebod K, Munk HL, Kristensen S, Manilo N, Colic A, Linauskas A, Thygesen PH, Christensen LB, Kalisz MH, Lomborg N, Chrysidis S, Raun JL, Andersen M, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Nabi H, et al. Among authors: manilo n. RMD Open. 2022 Nov;8(2):e002560. doi: 10.1136/rmdopen-2022-002560. RMD Open. 2022. PMID: 36418087 Free PMC article.
Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.
Terslev L, Ostergaard M, Georgiadis S, Brahe CH, Ellegaard K, Dohn UM, Fana V, Møller T, Juul L, Huynh TK, Krabbe S, Ornbjerg LM, Glinatsi D, Røgind H, Hansen A, Nørregaard J, Jacobsen S, Jensen DV, Manilo N, Asmussen K, Boesen M, Rastiemadabadi Z, Morsel-Carlsen L, Møller JM, Krogh NS, Hetland ML. Terslev L, et al. Among authors: manilo n. RMD Open. 2022 Dec;8(2):e002796. doi: 10.1136/rmdopen-2022-002796. RMD Open. 2022. PMID: 36549857 Free PMC article.
Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
Terslev L, Brahe CH, Hetland ML, Georgiadis S, Ellegaard K, Juul L, Huynh T, Døhn UM, Fana V, Møller T, Krabbe S, Ørnbjerg LM, Glinatsi D, Røgind H, Hansen A, Nørregaard J, Jacobsen S, Jensen DV, Manilo N, Asmussen K, Boesen M, Rastiemadabadi Z, Morsel-Carlsen L, Møller JM, Krogh NS, Østergaard M. Terslev L, et al. Among authors: manilo n. Rheumatology (Oxford). 2021 Dec 1;60(12):5549-5559. doi: 10.1093/rheumatology/keab276. Rheumatology (Oxford). 2021. PMID: 33748831
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
Brahe CH, Krabbe S, Østergaard M, Ørnbjerg L, Glinatsi D, Røgind H, Jensen HS, Hansen A, Nørregaard J, Jacobsen S, Terslev L, Huynh TK, Jensen DV, Manilo N, Asmussen K, Brown Frandsen P, Boesen M, Rastiemadabadi Z, Morsel Carlsen L, Møller JM, Krogh NS, Hetland ML. Brahe CH, et al. Among authors: manilo n. Rheumatology (Oxford). 2019 Jan 1;58(1):110-119. doi: 10.1093/rheumatology/key244. Rheumatology (Oxford). 2019. PMID: 30169706
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: manilo n. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5. Ann Rheum Dis. 2019. PMID: 30396903
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H, Georgiadis S, Loft AG, Hendricks O, Jensen DV, Andersen M, Chrysidis S, Colic A, Danebod K, Hussein MR, Kalisz MH, Kristensen S, Lomborg N, Manilo N, Munk HL, Pedersen JK, Raun JL, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Nabi H, et al. Among authors: manilo n. Ann Rheum Dis. 2021 Nov;80(11):1400-1409. doi: 10.1136/annrheumdis-2021-219951. Epub 2021 Apr 29. Ann Rheum Dis. 2021. PMID: 33926921
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.
Ibfelt EH, Sørensen J, Jensen DV, Dreyer L, Schiøttz-Christensen B, Thygesen PH, Colic A, Raun JL, Manilo N, Rødgaard A, Poulsen UE, Rasmussen C, Hansen T, Unger B, Pelck R, Kincses A, Nordin H, Lorenzen T, Theibich A, Jensen Hansen IM, Espesen J, Grydehøj J, Holland-Fischer M, Loft AG, Hetland ML. Ibfelt EH, et al. Among authors: manilo n. Clin Epidemiol. 2017 Nov 29;9:627-632. doi: 10.2147/CLEP.S141438. eCollection 2017. Clin Epidemiol. 2017. PMID: 29238225 Free PMC article.
Association between MRI findings and patient-reported outcomes in patients with rheumatoid arthritis in clinical remission and at relapse.
Glinatsi D, Brahe CH, Hetland ML, Ørnbjerg L, Krabbe S, Baker JF, Boesen M, Rastiemadabadi Z, Morsel-Carlsen L, Røgind H, Hansen A, Nørregaard J, Jacobsen S, Terslev L, Huynh TK, Manilo N, Jensen DV, Møller JM, Krogh NS, Østergaard M. Glinatsi D, et al. Among authors: manilo n. Int J Rheum Dis. 2020 Apr;23(4):488-498. doi: 10.1111/1756-185X.13790. Epub 2020 Jan 28. Int J Rheum Dis. 2020. PMID: 31994328
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K; OPERA Study-Group. Hørslev-Petersen K, et al. Ann Rheum Dis. 2014 Apr;73(4):654-61. doi: 10.1136/annrheumdis-2012-202735. Epub 2013 Feb 23. Ann Rheum Dis. 2014. PMID: 23434570 Clinical Trial.
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehøj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sørensen MV, Andersen LS, Grøn KL, Krogh NS, Pedersen L, Hetland ML; all departments of rheumatology in Denmark. Glintborg B, et al. Among authors: manilo n. Ann Rheum Dis. 2017 Aug;76(8):1426-1431. doi: 10.1136/annrheumdis-2016-210742. Epub 2017 May 4. Ann Rheum Dis. 2017. PMID: 28473425
17 results